Fate Therapeutics FATE

HealthcareMarket cap $300M0 connections

Fate Therapeutics develops iPSC-derived cell therapies - cancer-killing immune cells grown from a single master stem cell line rather than each patient's own cells. Off-the-shelf CAR-NK and CAR-T cells could make cancer immunotherapy accessible and affordable rather than custom-manufactured per patient.

Open Fate Therapeutics's Company Hub Simulate a merger Supply chain See it on the map

We haven't documented any relationships for this company yet.

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show Fate Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=FATE" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Fate Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.